NOT MEDICAL ADVICE. No information on this site should be considered medical advice. Research peptides are not intended for human consumption — in-vitro lab use only. Consult a physician prior to introducing anything into the human body.
Peptide HubResearch Peptide Wiki
Support Us Join

Retatrutide Phase 2 Data: How to Read the Numbers Without Fooling Yourself

A single 338-person trial is currently doing the marketing work of a full development program. Here is what the published phase 2 data actually support — and what they cannot.

The study in one paragraph

The main phase 2 trial of retatrutide is a randomized, double-blind, placebo-controlled study published in NEJM (2023). Roughly 338 adults with overweight or obesity received placebo or one of several once-weekly subcutaneous doses for up to 48 weeks. The questions on the table were dose response and tolerability — not long-term safety, and not comparison against other drugs.

The numbers everyone quotes

Reported group-average weight loss in the highest-dose arm reached about 17.5% at week 24 and approximately 24% by week 48.

Published phase 2 data (NEJM, 2023); group means in one dose arm of one study

Context that usually gets dropped along with the footnote: these are group averages, and participants within every group varied widely. The placebo group also lost some weight, so placebo-adjusted effects are smaller than the headline figures suggest. And in the top-dose arms the curve was still descending at week 48 — one reason the phase 3 program runs much longer. None of this makes the result unimpressive. It makes it a phase 2 result: a signal, not a specification.

The liver-fat finding: exploratory, not primary

Among participants with fatty liver at baseline who underwent MRI, dose-dependent reductions in liver fat were reported as an exploratory endpoint. That is encouraging and mechanistically coherent — but exploratory subgroup analyses are exactly the kind of result that dedicated trials confirm or quietly bury. Treat it as a hypothesis with momentum, not as an established effect.

What phase 2 cannot tell you

  • Rare or delayed safety signals need thousands of patient-years; a few hundred people over 48 weeks cannot surface them.
  • The composition of the loss — fat versus lean mass — beyond small substudies.
  • Cardiovascular outcomes, which the phase 3 program is designed to measure.
  • Comparative performance: this trial had no active-comparator arm against semaglutide, tirzepatide, or any other drug.
  • Which dose is “the” dose — several were tested, and dose selection is a phase 3 decision.

What to watch in phase 3

The TRIUMPH program is testing retatrutide across multiple populations over longer time horizons. Watch for: mean weight loss at 72-plus weeks, adverse-event and discontinuation rates, body-composition substudies, and any cardiovascular outcomes data. Until those read out, quoting the phase 2 percentages as settled fact is a category error — and vendors who do it are telling you exactly how they read science.